Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023)
Mimedx (MDXG) posted Preferred Stock Liabilities of $92.5 million for Q3 2023, little changed sequentially from $92.5 million in Q2 2023, and little changed YoY from $92.5 million in Q3 2022.
Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends
Mimedx has reported Preferred Stock Liabilities for 4 years, with the latest figure at $92.5 million in Q3 2023.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $92.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $92.5 million (changed 0.0% YoY) and the FY2022 annual result came in at $92.5 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $92.5 million in Q3 2023 per MDXG's latest filing, from $92.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $92.5 million in Q2 2021 and troughed at $91.1 million in Q3 2020.
- A 4-year average of $92.3 million and a median of $92.5 million in 2021 frame the typical range for Preferred Stock Liabilities.
- The sharpest annual moves came in 2021 and 2022: Preferred Stock Liabilities increased 1.52% in 2021, then changed 0.0% in 2022.
- Over 4 years, Preferred Stock Liabilities stood at $91.6 million in 2020, then advanced by 1.01% to $92.5 million in 2021, then changed by 0.0% to $92.5 million in 2022, then changed by 0.0% to $92.5 million in 2023.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $92.5 million, $92.5 million, and $92.5 million for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 92.49 Mn |
| Jun 30, 2023 | 92.49 Mn |
| Mar 31, 2023 | 92.49 Mn |
| Dec 31, 2022 | 92.49 Mn |
| Sep 30, 2022 | 92.49 Mn |
| Jun 30, 2022 | 92.49 Mn |
| Mar 31, 2022 | 92.49 Mn |
| Dec 31, 2021 | 92.49 Mn |
| Sep 30, 2021 | 92.49 Mn |
| Jun 30, 2021 | 92.49 Mn |
| Mar 31, 2021 | 92.03 Mn |
| Dec 31, 2020 | 91.57 Mn |
| Sep 30, 2020 | 91.11 Mn |